10-Q: Tourmaline Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Tourmaline Bio reports a net loss of $17.5 million for the second quarter of 2024, alongside updates on clinical trials and financial position.

Summary

• Tourmaline Bio, a late-stage clinical biotechnology company, announced its financial results for the second quarter ended June 30, 2024.
• The company reported a net loss of $17.5 million, or $0.68 per share, for the quarter, compared to a net loss of $16.1 million, or $16.29 per share, for the same period in 2023.
• Research and development expenses increased to $15.7 million for the quarter, up from $14.5 million in the prior year, primarily due to increased employee compensation and clinical trial costs.
• General and administrative expenses also rose significantly to $6.2 million, compared to $1.9 million in the same quarter of 2023, driven by increased headcount and consulting expenses.
• The company's cash, cash equivalents, and investments totaled $334.4 million as of June 30, 2024.
• Tourmaline Bio expects its current financial resources to fund operations into 2027.
• The company is advancing pacibekitug (TOUR006) in clinical trials for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
• A Phase 2b trial for TED (spiriTED) is ongoing, with topline data expected in 2025, and a Phase 3 trial is planned for the second half of 2024.
• A Phase 2 trial for ASCVD (TRANQUILITY) is also underway, with topline data expected in the first half of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has a strong cash position and is progressing with clinical trials, it also reports increased losses and identifies material weaknesses in internal controls. The future outlook is cautiously optimistic but dependent on successful clinical trial outcomes and potential capital raises.

Positives

• The company has a strong cash position of $334.4 million, which is expected to fund operations into 2027.
• The company is actively progressing its clinical trials for pacibekitug in multiple indications.
• The company has reached alignment with the FDA on the ASCVD clinical development program.
• The company has initiated a Phase 2 trial of pacibekitug in patients with chronic kidney disease (CKD) and elevated high-sensitivity CRP (hs-CRP).

Negatives

• The company reported a net loss of $17.5 million for the second quarter of 2024.
• Research and development expenses increased to $15.7 million in Q2 2024.
• General and administrative expenses rose significantly to $6.2 million in Q2 2024.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company has a limited operating history and no history of commercializing products.
• The company is highly dependent on the success of pacibekitug.
• The company will need significant additional capital to proceed with development and commercialization.
• The company relies completely on contract development and manufacturing organizations (CDMOs) for manufacturing.
• Clinical trials may be delayed, suspended, or terminated at any time.
• The company may not be able to obtain and maintain relationships with third parties.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may face unfavorable pricing regulations or reimbursement practices.
• The company may experience difficulties in managing its growth.
• The company's international operations may expose it to various risks.
• The company may be subject to product liability lawsuits.
• The company's relationships with healthcare providers will be subject to healthcare laws and regulations.
• The company's business could be affected by disease outbreaks, epidemics, and pandemics.
• The company's ability to use net operating loss carryforwards may be limited.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's internal control over financial reporting may not meet the standards required by Section 404 of the Sarbanes-Oxley Act.
• The company may experience a security incident, system disruption or failure, data loss, cyberattack, or similar event.

Future Outlook

The company expects its existing cash, cash equivalents and investments will enable it to fund its expected operating expenses and capital expenditure requirements for at least 12 months from August 8, 2024, and into 2027 based on current plans. The company expects to finance its future cash needs through a combination of equity or debt financings, collaborations, licensing arrangements and strategic alliances.

Management Comments

• Management expects that research and development expenses will increase substantially over the next several years as the company advances its product candidate into larger and later-stage clinical trials.
• Management expects that general and administrative expenses will increase in the future to support continued research and development activities and pre-commercial preparation activities.

Industry Context

The anti-IL-6 and anti-IL-6 receptor antibody class has over two decades of clinical and commercial experience, with four approved antibodies generating more than $3.5 billion in global sales in 2023. Tourmaline Bio is positioning pacibekitug as a potentially superior therapy in this class, particularly for autoantibody-driven diseases and cardiovascular inflammation.

Comparison to Industry Standards

• The document mentions that four anti-IL-6 or anti-IL-6R antibodies generated more than $3.5 billion in global sales in 2023, indicating a significant market for this class of drugs.
• The company is pursuing thyroid eye disease (TED) as a beachhead indication, noting the beneficial off-label use of Actemra (tocilizumab) in reducing inflammation and autoantibodies in TED patients, but no formal industry-sponsored development effort has been completed to date.
• The company is also targeting atherosclerotic cardiovascular disease (ASCVD), a leading cause of death globally, and notes that multiple external Phase 3 cardiovascular outcome trials investigating IL-6 blockade are ongoing, suggesting a competitive landscape but also a significant market opportunity.
• The company believes that pacibekitug potentially offers a meaningfully enhanced product profile to these competitor programs with a potential for subcutaneous dosing once every three months.

Management Changes

Legal Proceedings

• The company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business.
• The company believes there are currently no pending legal proceedings to which it or its property are subject that could have a material adverse effect on its financial position, results of operations or cash flows.

Related Party Transactions

• In May 2023, an advisor affiliated with Fourth Avenue FF Opportunities LP Series Z, previously a beneficial owner of the Companys outstanding capital stock, exercised stock options to purchase 75,782 shares of the Companys common stock for $0.13 per share.
• The Company subsequently repurchased the shares from the advisor at $2.76 per share, equivalent to fair value as of the repurchase date, for an aggregate purchase price of $0.2 million.
• Fourth Avenue FF Opportunities LP Series Z then purchased the shares from the Company at the same amount $2.76 per share for an aggregate purchase price of $0.2 million.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial performance and clinical trial progress.
• Employees may see changes in compensation and benefits as the company grows.
• Customers (potential patients) may benefit from new therapies if the company's product candidates are approved.
• Suppliers and creditors may be affected by the company's financial stability and ability to pay.
• The company's success will depend on its ability to attract and retain key scientific, medical, commercial and management personnel.

Next Steps

• The company expects to report topline data from the spiriTED trial in 2025.
• The company expects to commence a pivotal Phase 3 trial of pacibekitug in first-line TED in the second half of 2024.
• The company expects to report topline data from the TRANQUILITY trial in the first half of 2025.
• The company plans to identify additional indication opportunities for pacibekitug.
• The company continues to evaluate new in-licensing and acquisition opportunities.

Key Dates

Keywords

pacibekitug, TOUR006, thyroid eye disease, atherosclerotic cardiovascular disease, clinical trials, biotechnology, monoclonal antibody, interleukin-6, financial results, research and development